https://www.selleckchem.com/pr....oducts/acss2-inhibit
05; P .0001; Johns Hopkins University cohort), 64% versus 83% (HR, 2.77; P .0001; Mayo Clinic cohort), and 71% versus 97% (HR, 6.8; P= .0001; Brigham and Women's Hospital cohort). The signature also identified TP53 wild-type tumors molecularly analogous to TP53 mutant tumors, wherein high signature score correlated with worse 5-year MFS (50% vs. 82%; HR, 3.05; P .0001). This novel mutational signature predicted tumors with TP53 mutations, identified TP53 wild-type tumors analogous to mutant tumors, and was independen
Like
Comment
Share
